Anixa Biosciences Announces Issuance of Canadian Patent Strengthening International Protection for its Ovarian Cancer Vaccine Technology
Anixa Biosciences (NASDAQ: ANIX) received a Canadian patent for its ovarian cancer vaccine technology, expanding its international intellectual property protection. The patent, licensed from Cleveland Clinic, covers methods of immunizing against a protein domain linked to ovarian cancer. This complements Anixa's existing U.S. patent and supports its cancer vaccine portfolio, which includes a breast cancer vaccine that recently completed a Phase 1 trial.



